DS 8201

Drug Profile

DS 8201

Alternative Names: DS-8201a; DS8201

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer

Most Recent Events

  • 05 Jun 2017 Preliminary efficacy and adverse events results from a phase I trial in Breast and Gastric cancers presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 05 Jun 2017 Daiichi Sankyo plans a phase II trial for Breast cancer (Late-stage disease) and Gastric cancer
  • 01 Apr 2017 Preclinical data in Gastric cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top